In the News

PPD adds clinical research unit with ‘strong’ recruiting track record to its portfolio, enabling studies on patient populations ‘more reflective’ of the products’ end-users.

Dawie Wessels of AES comments on the cause and treatment of non-alcoholic steatohepatitis (NASH).

A shortage of high-quality sites are available for sponsors for certain indications and parts of the world. PPD recognized this obstacle and sought out to address this need.

How democratization of data is powering a new wave of opportunities.

Wilmington-based PPD now has a 52-bed clinical research unit in Orlando, Florida, with a focus on early phase trials on neurological disorders.

PPD’s Derek Wood discusses the critical importance of extractables and leachables (E&L) evaluations related to drug product safety, efficacy and quality.

PPD has launched a new service aimed at clinical research training for doctors and healthcare workers at new sites to help them stay the course.

Moving the industry from a focus on treatment to a focus on prevention will require data, new financial incentives, and a change in how healthcare is delivered and paid for.

PPD puts the spotlight on special patient populations by supporting clinical trials with Asian participants, preparing developers to expand into the Asian market.